Samsung Medison Joins Forces With Bracco Imaging To Enhance Ultrasound Diagnostic Technology

In a significant stride towards enhancing diagnostic ultrasound technology, Samsung Medison and Bracco Imaging have entered into a Memorandum of Understanding (MoU) to foster research and development in the domain of diagnostic ultrasound devices and contrast agents. This collaboration, announced at the European Congress of Radiology 2024, aims to optimize the use of ultrasound contrast agents, improve image resolution, streamline operational workflows, and deliver substantial clinical advantages to both practitioners and patients.

As a prominent manufacturer of premium ultrasound diagnostic equipment, Samsung Medison brings to the table its advanced technological capabilities. On the other hand, Bracco Imaging, with its global leadership in precision diagnostic imaging solutions, contributes a wealth of expertise in end-to-end product development. Together, they plan to undertake joint research initiatives focused on developing high-frequency and super-resolution imaging protocols for diagnostic purposes. Additionally, their collaboration extends to global marketing efforts aimed at educating healthcare providers and jointly participating in strategic industry events.

One of the pivotal goals of this partnership is to broaden the application spectrum of ultrasound contrast agents across various medical specialties and settings. This will be achieved by integrating Bracco Imaging's quantitative diagnostic analysis software with Samsung Medison's state-of-the-art diagnostic ultrasound equipment. Such integration is expected to enhance image reporting accuracy and convenience for medical professionals.

At the forefront of innovation, Samsung Medison showcased several new diagnostic ultrasound techniques at the European Congress of Radiology 2024. Noteworthy among these are Live BreastAssist™, an AI-driven feature for real-time lesion detection in breast examinations, and NerveTrack™, a real-time nerve tracking functionality. These advancements underscore Samsung Medison's commitment to elevating diagnostic precision and broadening the clinical applications of ultrasound technology through AI solutions.

The CEOs of both companies have expressed their enthusiasm about this partnership's potential to revolutionize the use of contrast agents in clinical treatments. They anticipate that this collaboration will catalyze technological innovations beneficial to patient care.

Bracco Imaging, headquartered in Milan, Italy, is a key player within the Bracco Group and maintains a presence in over 100 markets worldwide. The company's extensive portfolio encompasses a variety of diagnostic imaging modalities such as X-ray imaging, MRI, contrast-enhanced ultrasound (CEUS), and nuclear medicine. Samsung Medison has established itself as a global leader in the field of diagnostic imaging devices since becoming an affiliate company of Samsung Electronics in 2011. This affiliation has allowed Samsung Medison to leverage cutting-edge IT, image processing, semiconductor, and communication technologies in developing medical devices.

This collaboration between Samsung Medison and Bracco Imaging marks a significant milestone in the advancement of diagnostic imaging technology. By combining their strengths in technology and market reach, both companies are set to make substantial contributions to the field of medical diagnostics, ultimately benefiting healthcare providers and patients alike.